Programmed death-1 (PD-1) is an immunoinhibitory receptor expressed on lymphocytes. Interaction of PD-1 with its
ligand PD-
ligand 1 (PD-L1) delivers inhibitory signals and impairs proliferation,
cytokine production, and cytotoxicity of T cells. In our previous studies, we have developed anti-bovine PD-L1
monoclonal antibodies (mAbs) and reported that the PD-1/PD-L1 pathway was closely associated with T-cell exhaustion and
disease progression in bovine
chronic infections and canine
tumors. Furthermore, we found that
blocking antibodies that target PD-1 and PD-L1 restore T-cell functions and could be used in
immunotherapy in cattle and dogs. However, the immunological role of the PD-1/PD-L1 pathway for chronic
equine diseases, including
tumors, remains unclear. In this study, we identified
cDNA sequences of equine PD-1 (EqPD-1) and PD-L1 (EqPD-L1) and investigated the role of anti-bovine PD-L1 mAbs against EqPD-L1 using in vitro assays. In addition, we evaluated the expression of PD-L1 in
tumor tissues of equine
malignant melanoma (EMM). The amino acid sequences of EqPD-1 and EqPD-L1 share a considerable identity and similarity with homologs from non-primate species. Two clones of the anti-bovine PD-L1 mAbs recognized EqPD-L1 in flow cytometry, and one of these cross-reactive mAbs blocked the binding of equine PD-1/PD-L1. Of note, immunohistochemistry confirmed the PD-L1 expression in EMM
tumor tissues. A cultivation assay revealed that PD-L1 blockade enhanced the production of Th1
cytokines in equine immune cells. These findings showed that our anti-PD-L1 mAbs would be useful for analyzing the equine PD-1/PD-L1 pathway. Further research is warranted to discover the immunological role of PD-1/PD-L1 in chronic
equine diseases and elucidate a future application in
immunotherapy for horses.